首页 > 最新文献

JCEM case reports最新文献

英文 中文
Thyroid Paraganglioma: A Rare Manifestation of Paraganglioma Syndrome Associated With Pathogenic Variant in SDHD. 甲状旁腺瘤:副神经节瘤综合征的一种罕见表现与 SDHD 的致病变异有关。
Pub Date : 2024-08-16 eCollection Date: 2024-09-01 DOI: 10.1210/jcemcr/luae135
Valentina D Tarasova, Kelara Samuel, Caitlin McMullen, Sergiy Kushchayev, Juan C Hernandez Prera, Colleen Veloski

Evaluation of an incidentally discovered indeterminate thyroid nodule (TN) in a previously healthy 59-year female led to diagnosis of thyroid paraganglioma (TPGL) and subsequently hereditary succinate dehydrogenase complex subunit D (SDHD)-related multifocal head and neck paragangliomas (PGLs). An ultrasound-guided fine needle aspiration (FNA) biopsy of the 1.7-cm TN was nondiagnostic and core biopsy was suspicious for papillary thyroid carcinoma. Pathology slides reviewed at tertiary center showed neuroendocrine neoplasm consistent with PGL. Her 24-hour urinary catecholamines and metanephrines were normal. Given the diagnosis of TPGL, genetic testing was recommended, which identified a pathogenic variant in SDHD (c.242C > T(p.P81L). Gallium-68-DOTATATE PET/CT revealed multifocal areas of increased somatostatin receptor expression from the skull base to thoracic inlet. Magnetic resonance imaging of the brain/neck showed multiple PGLs (right jugular, carotid, thyroid, left vagal, left level II, and superior mediastinal), all measured up to 1.7 cm. The right jugular PGL was treated with external beam radiation therapy of 3000 cGy. All PGLs remained stable and asymptomatic at 22-month follow-up imaging. TPGL should be considered in the differential diagnosis of a hypervascular TN in patients with SDHx-related pheochromocytoma-PGL syndromes and when such lesions with indeterminate cytology are encountered in patients with no known history of SDHx-mutation or syndrome.

一位59岁的健康女性偶然发现了一个不确定的甲状腺结节(TN),对其进行评估后确诊为甲状腺副神经节瘤(TPGL),随后又确诊为遗传性琥珀酸脱氢酶复合体亚基D(SDHD)相关多灶性头颈部副神经节瘤(PGLs)。在超声引导下对1.7厘米的TN进行细针穿刺(FNA)活检,结果无法确诊,而核心活检则怀疑是甲状腺乳头状癌。在三级中心进行的病理切片审查显示,神经内分泌肿瘤与PGL一致。她的 24 小时尿儿茶酚胺和甲肾上腺素均正常。鉴于诊断为 TPGL,建议进行基因检测,结果发现 SDHD 存在致病变异(c.242C > T(p.P81L))。镓-68-DOTATATE正电子发射计算机断层扫描(PET/CT)显示,从颅底到胸腔入口的多灶性区域体生长抑素受体表达增加。脑/颈部磁共振成像显示有多个PGL(右颈静脉、颈动脉、甲状腺、左迷走神经、左侧二级和上纵隔),所有PGL的大小均达到1.7厘米。右颈静脉 PGL 接受了 3000 cGy 的体外放射治疗。在 22 个月的随访造影中,所有 PGL 均保持稳定且无症状。在鉴别诊断与SDHx相关的嗜铬细胞瘤-PGL综合征患者的高血管性TN时,以及在没有已知SDHx突变或综合征病史的患者中遇到细胞学不确定的病变时,应考虑TPGL。
{"title":"Thyroid Paraganglioma: A Rare Manifestation of Paraganglioma Syndrome Associated With Pathogenic Variant in <i>SDHD</i>.","authors":"Valentina D Tarasova, Kelara Samuel, Caitlin McMullen, Sergiy Kushchayev, Juan C Hernandez Prera, Colleen Veloski","doi":"10.1210/jcemcr/luae135","DOIUrl":"10.1210/jcemcr/luae135","url":null,"abstract":"<p><p>Evaluation of an incidentally discovered indeterminate thyroid nodule (TN) in a previously healthy 59-year female led to diagnosis of thyroid paraganglioma (TPGL) and subsequently hereditary succinate dehydrogenase complex subunit D (<i>SDHD)</i>-related multifocal head and neck paragangliomas (PGLs). An ultrasound-guided fine needle aspiration (FNA) biopsy of the 1.7-cm TN was nondiagnostic and core biopsy was suspicious for papillary thyroid carcinoma. Pathology slides reviewed at tertiary center showed neuroendocrine neoplasm consistent with PGL. Her 24-hour urinary catecholamines and metanephrines were normal. Given the diagnosis of TPGL, genetic testing was recommended, which identified a pathogenic variant in <i>SDHD</i> (c.242C > T(p.P81L). Gallium-68-DOTATATE PET/CT revealed multifocal areas of increased somatostatin receptor expression from the skull base to thoracic inlet. Magnetic resonance imaging of the brain/neck showed multiple PGLs (right jugular, carotid, thyroid, left vagal, left level II, and superior mediastinal), all measured up to 1.7 cm. The right jugular PGL was treated with external beam radiation therapy of 3000 cGy. All PGLs remained stable and asymptomatic at 22-month follow-up imaging. TPGL should be considered in the differential diagnosis of a hypervascular TN in patients with <i>SDH</i>x-related pheochromocytoma-PGL syndromes and when such lesions with indeterminate cytology are encountered in patients with no known history of <i>SDHx</i>-mutation or syndrome.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 9","pages":"luae135"},"PeriodicalIF":0.0,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypercalcemia in Pregnancy Caused by a Uterine Myoma. 子宫肌瘤导致的妊娠高钙血症
Pub Date : 2024-08-14 eCollection Date: 2024-09-01 DOI: 10.1210/jcemcr/luae126
Stephanie van der Leij, Doenja Hertog

We present a case of a PTH-related peptide (PTH-rp) producing uterine myoma, leading to hypercalcemia in pregnancy. Our patient presented with dehydration, hypotension, delirium, and malnutrition. Due to a serum calcium level of 17.9 mg/dL (4.48 mmol/L) (reference range 8.8-11.2 mg/dL; 2.20-2.80 mmol/L), prompt treatment with hydration and calcitonin was initiated. The patient went into labor before we could consider other treatment options. Although uncommon in pregnancy, it is of great importance to identify hypercalcemia since it is related to a high risk of maternal and neonatal morbidity and mortality. Because bisphosphonates are contraindicated in pregnancy, hydration and calcitonin are the cornerstones of treatment for PTH-rp-induced hypercalcemia.

我们介绍了一例产生 PTH 相关肽(PTH-rp)的子宫肌瘤,导致妊娠期高钙血症的病例。患者出现脱水、低血压、谵妄和营养不良。由于血清钙水平为 17.9 mg/dL(4.48 mmol/L)(参考值范围为 8.8-11.2 mg/dL;2.20-2.80 mmol/L),我们立即开始了补液和降钙素治疗。在我们考虑其他治疗方案之前,患者已经分娩。虽然高钙血症在妊娠期并不常见,但由于它与孕产妇和新生儿发病率和死亡率的高风险有关,因此识别高钙血症非常重要。由于孕期禁用双膦酸盐,因此水合作用和降钙素是治疗 PTH-rp 引起的高钙血症的基础。
{"title":"Hypercalcemia in Pregnancy Caused by a Uterine Myoma.","authors":"Stephanie van der Leij, Doenja Hertog","doi":"10.1210/jcemcr/luae126","DOIUrl":"10.1210/jcemcr/luae126","url":null,"abstract":"<p><p>We present a case of a PTH-related peptide (PTH-rp) producing uterine myoma, leading to hypercalcemia in pregnancy. Our patient presented with dehydration, hypotension, delirium, and malnutrition. Due to a serum calcium level of 17.9 mg/dL (4.48 mmol/L) (reference range 8.8-11.2 mg/dL; 2.20-2.80 mmol/L), prompt treatment with hydration and calcitonin was initiated. The patient went into labor before we could consider other treatment options. Although uncommon in pregnancy, it is of great importance to identify hypercalcemia since it is related to a high risk of maternal and neonatal morbidity and mortality. Because bisphosphonates are contraindicated in pregnancy, hydration and calcitonin are the cornerstones of treatment for PTH-rp-induced hypercalcemia.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 9","pages":"luae126"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141986720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use. 使用商业性能增强补充剂导致的可逆性妇科肿瘤和性腺功能减退症。
Pub Date : 2024-08-14 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae148
Serena Chong, Catherine A Woolnough, Sundar R Koyyalamudi, Nimalie J Perera

Commercially available performance-enhancing supplements can contain banned performance-enhancing drugs (PEDs) and undisclosed steroid hormones that can induce hormonal abnormalities with associated clinical signs. We present a case of a 40-year-old male who developed bilateral gynecomastia and biochemical hypogonadotropic hypogonadism with a corresponding 6-month history of consuming commercially available performance-enhancing supplements for gym workouts. These performance-enhancing supplements were found to contain amounts of RAD-140, a selective androgen receptor modulator, MK-677, a GH secretagogue and cardarine, all of which are banned PEDs. In vitro analysis also detected undisclosed hormones testosterone, estradiol, and GH in all 3 supplements, with further steroid analysis using liquid chromatography mass spectrometry identifying an unidentified compound coeluting close to the testosterone peak. Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism. This case highlights the need for clinicians to consider commercially available performance-enhancing supplements as potential sources of PEDs and exogenous steroid hormones that can have adverse clinical consequences.

市售的提高运动能力补充剂可能含有禁用的提高运动能力药物(PED)和未公开的类固醇激素,可诱发激素异常并伴有相关临床症状。我们介绍了一例 40 岁的男性病例,他在健身房锻炼时服用了市售的提高运动成绩补充剂 6 个月后,出现了双侧妇科乳腺增生和生化性腺功能减退症。经检测,这些提高运动能力的保健品中含有大量的选择性雄激素受体调节剂 RAD-140、促生长激素分泌剂 MK-677 和卡达林,所有这些都是被禁用的 PEDs。体外分析还在所有 3 种补充剂中检测到了未公开的激素睾酮、雌二醇和促生长激素,使用液相色谱质谱法进行的进一步类固醇分析发现,在睾酮峰附近有一种不明化合物。停止服用这些保健品后,症状完全消失,包括性腺功能减退症恢复正常。本病例强调,临床医生需要将市售的提高成绩补充剂视为可能产生不良临床后果的 PED 和外源性类固醇激素的潜在来源。
{"title":"Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use.","authors":"Serena Chong, Catherine A Woolnough, Sundar R Koyyalamudi, Nimalie J Perera","doi":"10.1210/jcemcr/luae148","DOIUrl":"10.1210/jcemcr/luae148","url":null,"abstract":"<p><p>Commercially available performance-enhancing supplements can contain banned performance-enhancing drugs (PEDs) and undisclosed steroid hormones that can induce hormonal abnormalities with associated clinical signs. We present a case of a 40-year-old male who developed bilateral gynecomastia and biochemical hypogonadotropic hypogonadism with a corresponding 6-month history of consuming commercially available performance-enhancing supplements for gym workouts. These performance-enhancing supplements were found to contain amounts of RAD-140, a selective androgen receptor modulator, MK-677, a GH secretagogue and cardarine, all of which are banned PEDs. In vitro analysis also detected undisclosed hormones testosterone, estradiol, and GH in all 3 supplements, with further steroid analysis using liquid chromatography mass spectrometry identifying an unidentified compound coeluting close to the testosterone peak. Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism. This case highlights the need for clinicians to consider commercially available performance-enhancing supplements as potential sources of PEDs and exogenous steroid hormones that can have adverse clinical consequences.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae148"},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid Arteriovenous Malformation in Hereditary Hemorrhagic Telangiectasia: Insights on Successful Noninvasive Imaging. 遗传性出血性远端血管扩张症中的甲状腺动静脉畸形:无创成像的成功启示。
Pub Date : 2024-08-12 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae138
Hisanori Goto, Iyo Tanimura, Yujiro Nakano, Yumie Takeshita, Toshinari Takamura

Hereditary hemorrhagic telangiectasia (HHT) causes arteriovenous malformations (AVMs) in several organs. This report is the first to document and image a thyroid AVM complication in HHT. A 72-year-old woman with HHT was referred for thyroid nodule evaluation. Ultrasonography showed a hypervascularized nodule in the right thyroid lobe which was initially suspected to be malignant. However, 3-dimensional computed tomography angiography demonstrated a thyroid AVM with abnormal anastomosis of the superior thyroid artery and the inferior thyroid vein. In the formation of thyroid AVM, here, chronic thyroiditis and hypothyroidism complications may have been a second hit, due to the predisposing first-hit germline mutation. This report sheds light on overlooked thyroid lesions in HHT and advocates a noninvasive imaging approach in diagnosing thyroid AVMs. Furthermore, this case suggests a potential mechanism of AVM formation in human HHT, possibly supporting the second-hit hypothesis.

遗传性出血性毛细血管扩张症(HHT)会导致多个器官出现动静脉畸形(AVM)。本报告首次对 HHT 并发甲状腺动静脉畸形进行了记录和成像。一名 72 岁的 HHT 女性患者被转诊接受甲状腺结节评估。超声波检查显示右侧甲状腺叶有一个高血管化结节,起初怀疑是恶性的。然而,三维计算机断层扫描血管造影显示甲状腺动静脉畸形,甲状腺上动脉和甲状腺下静脉吻合异常。在甲状腺动静脉畸形的形成过程中,慢性甲状腺炎和甲状腺功能减退并发症可能是第二次发作,这是因为第一次发作的种系突变具有易感性。本报告揭示了HHT患者中被忽视的甲状腺病变,并提倡采用无创影像学方法诊断甲状腺动静脉畸形。此外,该病例还提示了人类HHT中AVM形成的潜在机制,可能支持二次突变假说。
{"title":"Thyroid Arteriovenous Malformation in Hereditary Hemorrhagic Telangiectasia: Insights on Successful Noninvasive Imaging.","authors":"Hisanori Goto, Iyo Tanimura, Yujiro Nakano, Yumie Takeshita, Toshinari Takamura","doi":"10.1210/jcemcr/luae138","DOIUrl":"10.1210/jcemcr/luae138","url":null,"abstract":"<p><p>Hereditary hemorrhagic telangiectasia (HHT) causes arteriovenous malformations (AVMs) in several organs. This report is the first to document and image a thyroid AVM complication in HHT. A 72-year-old woman with HHT was referred for thyroid nodule evaluation. Ultrasonography showed a hypervascularized nodule in the right thyroid lobe which was initially suspected to be malignant. However, 3-dimensional computed tomography angiography demonstrated a thyroid AVM with abnormal anastomosis of the superior thyroid artery and the inferior thyroid vein. In the formation of thyroid AVM, here, chronic thyroiditis and hypothyroidism complications may have been a second hit, due to the predisposing first-hit germline mutation. This report sheds light on overlooked thyroid lesions in HHT and advocates a noninvasive imaging approach in diagnosing thyroid AVMs. Furthermore, this case suggests a potential mechanism of AVM formation in human HHT, possibly supporting the second-hit hypothesis.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae138"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-Guided Microwave Ablation of Thyroid Schwannoma. 超声引导下的甲状腺许旺瘤微波消融术
Pub Date : 2024-08-12 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae146
Xue Han, Yuzhi Zhang, Yu Li, Ruiping Li, Chao Liu, Shuhang Xu

Thyroid schwannoma, a rare neoplasm of the thyroid gland, originates from Schwann cells that form the myelin sheath. A 47-year-old woman presented with a progressively enlarging thyroid nodule, which was monitored by repeated ultrasonography over the previous 2 years. Following a diagnosis of thyroid schwannoma by core needle biopsy and immunohistochemical staining, the patient underwent ultrasound-guided microwave ablation (MWA). Subsequent thyroid ultrasounds indicated a gradual decrease in the tumor's volume, achieving a 12-month volume reduction ratio of 79.20%. No complications were observed. Ultrasound-guided MWA may serve as an effective alternative to conventional surgery for managing thyroid schwannomas.

甲状腺分裂瘤是一种罕见的甲状腺肿瘤,起源于形成髓鞘的许旺细胞。一名 47 岁的妇女因甲状腺结节逐渐增大而就诊,在过去的两年中,她通过反复的超声波检查对结节进行了监测。经芯针活检和免疫组化染色确诊为甲状腺分裂瘤后,患者接受了超声引导下的微波消融术(MWA)。随后的甲状腺超声检查显示肿瘤体积逐渐缩小,12个月的体积缩小率为79.20%。术后未发现并发症。超声引导下微波消融术可以有效替代传统手术治疗甲状腺裂孔瘤。
{"title":"Ultrasound-Guided Microwave Ablation of Thyroid Schwannoma.","authors":"Xue Han, Yuzhi Zhang, Yu Li, Ruiping Li, Chao Liu, Shuhang Xu","doi":"10.1210/jcemcr/luae146","DOIUrl":"10.1210/jcemcr/luae146","url":null,"abstract":"<p><p>Thyroid schwannoma, a rare neoplasm of the thyroid gland, originates from Schwann cells that form the myelin sheath. A 47-year-old woman presented with a progressively enlarging thyroid nodule, which was monitored by repeated ultrasonography over the previous 2 years. Following a diagnosis of thyroid schwannoma by core needle biopsy and immunohistochemical staining, the patient underwent ultrasound-guided microwave ablation (MWA). Subsequent thyroid ultrasounds indicated a gradual decrease in the tumor's volume, achieving a 12-month volume reduction ratio of 79.20%. No complications were observed. Ultrasound-guided MWA may serve as an effective alternative to conventional surgery for managing thyroid schwannomas.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae146"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. 帕西瑞奥肽能迅速缓解肢端肥大症成人患者的顽固性头痛
Pub Date : 2024-08-09 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae142
Zeinab Dabbous, Zaina Rohani, Abeer Kaled Abdalrubb, Yaman Alkailani, Rosario Pivonello, Tarik Elhadd

Acromegaly is a chronic hormonal disorder caused by excessive GH secretion. In addition to physiological symptoms, it is often accompanied by debilitating headaches. Although effective treatment options exist, achieving complete symptom control and disease management can still be challenging. This case report chronicles the clinical journey of a 38-year-old male diagnosed with acromegaly in 2013. Despite prior interventions, including surgery and treatment with first-generation somatostatin analogues, severe frequent headaches persisted. Following a switch to pasireotide, the patient reported rapid and complete resolution of headaches and normalization of IGF-1 levels within a month of the treatment switch. This report underscores the challenges in acromegaly management and confirms the potential utility of pasireotide for patients suffering from treatment-resistant headache.

肢端肥大症是一种由 GH 分泌过多引起的慢性内分泌失调症。除了生理症状外,它还经常伴有使人衰弱的头痛。虽然存在有效的治疗方案,但要完全控制症状和控制病情仍然具有挑战性。本病例报告记录了一名 38 岁男性于 2013 年被诊断为肢端肥大症的临床历程。尽管之前采取了包括手术和第一代体生长激素类似物治疗在内的干预措施,但严重的频繁头痛仍然存在。在改用帕司瑞肽治疗后,患者报告头痛迅速完全缓解,IGF-1水平也在一个月内恢复正常。该报告强调了肢端肥大症治疗所面临的挑战,并证实了帕西瑞肽对治疗耐药头痛患者的潜在作用。
{"title":"Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly.","authors":"Zeinab Dabbous, Zaina Rohani, Abeer Kaled Abdalrubb, Yaman Alkailani, Rosario Pivonello, Tarik Elhadd","doi":"10.1210/jcemcr/luae142","DOIUrl":"10.1210/jcemcr/luae142","url":null,"abstract":"<p><p>Acromegaly is a chronic hormonal disorder caused by excessive GH secretion. In addition to physiological symptoms, it is often accompanied by debilitating headaches. Although effective treatment options exist, achieving complete symptom control and disease management can still be challenging. This case report chronicles the clinical journey of a 38-year-old male diagnosed with acromegaly in 2013. Despite prior interventions, including surgery and treatment with first-generation somatostatin analogues, severe frequent headaches persisted. Following a switch to pasireotide, the patient reported rapid and complete resolution of headaches and normalization of IGF-1 levels within a month of the treatment switch. This report underscores the challenges in acromegaly management and confirms the potential utility of pasireotide for patients suffering from treatment-resistant headache.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae142"},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neonatal Severe Hyperparathyroidism Causing Life-Threatening Hypercalcemia Treated With Medical and Surgical Management. 新生儿严重甲状旁腺功能亢进症导致危及生命的高钙血症,采用内科和外科手术治疗。
Pub Date : 2024-08-09 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae133
Kerri Rosettenstein, Andrew Parasyn, Kristen Neville, Shihab Hameed

A 3-day-old male presented to a peripheral remote hospital in New South Wales, Australia, with tachypnea. He was found to have hypercalcemia, with ionized calcium >2.5 mmol/L (>10 mg/dL) (0.97-1.5 mmol/L or 1.14-1.3 mg/dL) and serum calcium of 3.85 mmol/L (15.43 mg/dL) (2.2-2.8 mmol/L or 8.5-10.5 mg/dL). Peak serum calcium was 5.4 mmol/L (21.64 mg/dL). He was transferred to a tertiary pediatric intensive care unit. Medical management (including hyperhydration, diuretics, corticosteroids, bisphosphonates, cinacalcet, and calcitonin) failed to maintain normocalcemia; therefore, total parathyroidectomy was performed on day 16 of life. Hungry bones syndrome developed postoperatively, requiring high doses of calcium, calcitriol, and phosphate supplementation. Genetic testing identified compound heterozygosity for 2 likely pathogenic variants in the calcium-sensing receptor gene. He is now 3 years old and is growing and developing without any concerns. This case highlights the importance of aggressive initial management in addressing severe hypercalcemia through perioperative management principles as well as the prolonged nature of hungry bones syndrome.

澳大利亚新南威尔士州一家外围偏远医院收治了一名 3 天大的男性患儿,当时他呼吸急促。他被发现患有高钙血症,离子钙大于 2.5 mmol/L(大于 10 mg/dL)(0.97-1.5 mmol/L 或 1.14-1.3 mg/dL),血清钙为 3.85 mmol/L(15.43 mg/dL)(2.2-2.8 mmol/L 或 8.5-10.5 mg/dL)。血钙峰值为 5.4 mmol/L(21.64 mg/dL)。他被转入三级儿科重症监护病房。药物治疗(包括高补液、利尿剂、皮质类固醇、双磷酸盐、西那卡西酮和降钙素)未能维持正常血钙,因此在出生后第16天进行了甲状旁腺全切除术。术后出现了 "饿骨症",需要补充大剂量的钙、降钙素三醇和磷酸盐。基因检测确定了钙传感受体基因中两个可能致病变体的复合杂合性。他现在已经 3 岁了,生长发育良好,没有任何问题。本病例强调了通过围手术期管理原则进行积极的初始管理以解决严重高钙血症的重要性,以及饿骨症的长期性。
{"title":"Neonatal Severe Hyperparathyroidism Causing Life-Threatening Hypercalcemia Treated With Medical and Surgical Management.","authors":"Kerri Rosettenstein, Andrew Parasyn, Kristen Neville, Shihab Hameed","doi":"10.1210/jcemcr/luae133","DOIUrl":"10.1210/jcemcr/luae133","url":null,"abstract":"<p><p>A 3-day-old male presented to a peripheral remote hospital in New South Wales, Australia, with tachypnea. He was found to have hypercalcemia, with ionized calcium >2.5 mmol/L (>10 mg/dL) (0.97-1.5 mmol/L or 1.14-1.3 mg/dL) and serum calcium of 3.85 mmol/L (15.43 mg/dL) (2.2-2.8 mmol/L or 8.5-10.5 mg/dL). Peak serum calcium was 5.4 mmol/L (21.64 mg/dL). He was transferred to a tertiary pediatric intensive care unit. Medical management (including hyperhydration, diuretics, corticosteroids, bisphosphonates, cinacalcet, and calcitonin) failed to maintain normocalcemia; therefore, total parathyroidectomy was performed on day 16 of life. Hungry bones syndrome developed postoperatively, requiring high doses of calcium, calcitriol, and phosphate supplementation. Genetic testing identified compound heterozygosity for 2 likely pathogenic variants in the calcium-sensing receptor gene. He is now 3 years old and is growing and developing without any concerns. This case highlights the importance of aggressive initial management in addressing severe hypercalcemia through perioperative management principles as well as the prolonged nature of hungry bones syndrome.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae133"},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ectopic Cushing Syndrome Secondary to Diffuse Idiopathic Neuroendocrine Cell Hyperplasia-A Report of 2 Cases. 继发于弥漫性特发性神经内分泌细胞增生症的异位库欣综合征--2 个病例的报告。
Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae128
Raul Lopez Fanas, Travis Goettemoeller, Keerthi Cedeno, Anjali D Manavalan

Ectopic ACTH secretion (EAS) accounts for 10% to 20% of all Cushing syndrome cases. Diffuse intrapulmonary neuroendocrine cell hyperplasia (DIPNECH), a poorly understood lung disease, is characterized by abnormal proliferation of neuroendocrine cells in the bronchial mucosa. It is thought to be a precursor of pulmonary carcinoid and has been associated with EAS in a handful of cases. We present 2 patients with clinical, radiological, and pathological features of DIPNECH who presented with florid Cushing syndrome secondary to EAS evidenced by rapid onset of symptoms, elevated plasma ACTH, and cortisol levels, and failed high-dose dexamethasone suppression testing. Treatment of hypercortisolism included excision of the involved lung and medical therapy with steroidogenesis inhibitors. Despite the aggressive initial management, hypercortisolism persisted. This case series highlights the importance of considering DIPNECH as a cause for Cushing syndrome in the appropriate clinical scenario and underscores the likelihood that surgery may not be curative because of the diffuse nature of this disease. Given the high mortality associated with EAS, prompt medical therapy, appropriate prophylaxis, and bilateral adrenalectomy can be lifesaving measures when initial surgery fails.

异位促肾上腺皮质激素分泌(EAS)占库欣综合征病例总数的 10%至 20%。弥漫性肺内神经内分泌细胞增生症(DIPNECH)是一种鲜为人知的肺部疾病,其特点是支气管粘膜神经内分泌细胞异常增生。它被认为是肺类癌的前兆,在少数病例中与 EAS 有关。我们报告了两名具有 DIPNECH 临床、放射学和病理学特征的患者,他们继发于 EAS,表现为症状发作迅速、血浆促肾上腺皮质激素和皮质醇水平升高,以及大剂量地塞米松抑制试验失败。高皮质醇症的治疗包括切除受累肺部和使用类固醇生成抑制剂。尽管最初采取了积极的治疗措施,但高皮质醇症仍持续存在。这组病例强调了在适当的临床情况下将 DIPNECH 作为库欣综合征病因的重要性,并强调了由于这种疾病的弥漫性,手术可能无法治愈。鉴于 EAS 的死亡率很高,当初始手术失败时,及时的药物治疗、适当的预防措施和双侧肾上腺切除术可能是挽救生命的措施。
{"title":"Ectopic Cushing Syndrome Secondary to Diffuse Idiopathic Neuroendocrine Cell Hyperplasia-A Report of 2 Cases.","authors":"Raul Lopez Fanas, Travis Goettemoeller, Keerthi Cedeno, Anjali D Manavalan","doi":"10.1210/jcemcr/luae128","DOIUrl":"10.1210/jcemcr/luae128","url":null,"abstract":"<p><p>Ectopic ACTH secretion (EAS) accounts for 10% to 20% of all Cushing syndrome cases. Diffuse intrapulmonary neuroendocrine cell hyperplasia (DIPNECH), a poorly understood lung disease, is characterized by abnormal proliferation of neuroendocrine cells in the bronchial mucosa. It is thought to be a precursor of pulmonary carcinoid and has been associated with EAS in a handful of cases. We present 2 patients with clinical, radiological, and pathological features of DIPNECH who presented with florid Cushing syndrome secondary to EAS evidenced by rapid onset of symptoms, elevated plasma ACTH, and cortisol levels, and failed high-dose dexamethasone suppression testing. Treatment of hypercortisolism included excision of the involved lung and medical therapy with steroidogenesis inhibitors. Despite the aggressive initial management, hypercortisolism persisted. This case series highlights the importance of considering DIPNECH as a cause for Cushing syndrome in the appropriate clinical scenario and underscores the likelihood that surgery may not be curative because of the diffuse nature of this disease. Given the high mortality associated with EAS, prompt medical therapy, appropriate prophylaxis, and bilateral adrenalectomy can be lifesaving measures when initial surgery fails.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae128"},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of ATRX Protein Expression in an Aggressive Null Cell Pituitary Tumor. 侵袭性零细胞垂体瘤中 ATRX 蛋白表达的缺失
Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae143
Elisa Lamback, Renan Lyra Miranda, Nina Ventura, Leila Chimelli, Mônica R Gadelha

Somatic alpha thalassemia/mental retardation syndrome X-linked (ATRX) pathogenic variants have been shown to predict a malignant phenotype in neuroendocrine tumors. They were recently identified in aggressive pituitary tumors and carcinomas, mainly of corticotrophic origin. To our knowledge, these tumors are rare in a general cohort of pituitary tumors, with no cases described in null cell tumors. These variants can lead to loss of protein expression as revealed by immunohistochemistry. We describe a case of an aggressive null cell pituitary tumor with loss of ATRX expression. The patient underwent two transsphenoidal surgeries and radiotherapy and exhibited tumor growth despite conventional therapy. Analysis of the tumor samples revealed loss of ATRX expression in both surgical specimens, suggesting that ATRX may be a useful biomarker for the early identification of aggressive pituitary tumors.

体细胞型阿尔法地中海贫血/智力低下综合征 X 连锁(ATRX)致病变体已被证明可预测神经内分泌肿瘤的恶性表型。最近在侵袭性垂体瘤和癌中发现了这些变体,主要是皮质营养源性垂体瘤和癌。据我们所知,这些肿瘤在一般的垂体瘤中很少见,在空细胞瘤中也没有发现。这些变异可导致免疫组化显示的蛋白表达缺失。我们描述了一例伴有ATRX表达缺失的侵袭性空细胞垂体瘤。患者接受了两次经蝶手术和放射治疗,尽管接受了常规治疗,但肿瘤仍在生长。对肿瘤样本的分析表明,两次手术标本中均有ATRX表达缺失,这表明ATRX可能是早期识别侵袭性垂体瘤的有用生物标记物。
{"title":"Loss of ATRX Protein Expression in an Aggressive Null Cell Pituitary Tumor.","authors":"Elisa Lamback, Renan Lyra Miranda, Nina Ventura, Leila Chimelli, Mônica R Gadelha","doi":"10.1210/jcemcr/luae143","DOIUrl":"10.1210/jcemcr/luae143","url":null,"abstract":"<p><p>Somatic <i>alpha thalassemia/mental retardation syndrome X-linked (ATRX)</i> pathogenic variants have been shown to predict a malignant phenotype in neuroendocrine tumors. They were recently identified in aggressive pituitary tumors and carcinomas, mainly of corticotrophic origin. To our knowledge, these tumors are rare in a general cohort of pituitary tumors, with no cases described in null cell tumors. These variants can lead to loss of protein expression as revealed by immunohistochemistry. We describe a case of an aggressive null cell pituitary tumor with loss of ATRX expression. The patient underwent two transsphenoidal surgeries and radiotherapy and exhibited tumor growth despite conventional therapy. Analysis of the tumor samples revealed loss of ATRX expression in both surgical specimens, suggesting that ATRX may be a useful biomarker for the early identification of aggressive pituitary tumors.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae143"},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal Obesity-Metabolic Syndrome 3 Misclassified as Type 1 Diabetes Mellitus. 腹部肥胖-代谢综合征 3 被误诊为 1 型糖尿病。
Pub Date : 2024-08-06 eCollection Date: 2024-08-01 DOI: 10.1210/jcemcr/luae120
Suhaib Radi, Lujain Bashamakh, Hayfa Mandourah, Sarah Alsharif

Age is no longer the most important differentiating feature between type 1 and type 2 diabetes, as obesity and metabolic syndrome are on the rise in the pediatric population. Here we present a case of a 30-year-old male individual initially diagnosed with uncontrolled type 1 diabetes mellitus (T1DM) since the age of 15, and treatment with high insulin doses has been unsuccessful. He was later identified as having abdominal obesity-metabolic syndrome 3 (AOMS3) based on strong family history and the presence of insulin resistance features. AOMS3 is characterized by early-onset coronary artery disease, central obesity, hypertension, and diabetes. Early detection of this condition is crucial to implement timely interventions and preventing the onset of complications.

年龄不再是区分 1 型糖尿病和 2 型糖尿病的最重要特征,因为肥胖和代谢综合征在儿童群体中呈上升趋势。我们在此介绍一例 30 岁男性患者的病例,他最初被诊断为自 15 岁以来一直未得到控制的 1 型糖尿病(T1DM),使用大剂量胰岛素治疗一直不成功。后来,他因家族遗传史和胰岛素抵抗特征而被确诊为腹型肥胖-代谢综合征 3(AOMS3)。腹型肥胖-代谢综合征 3 的特征是早发冠心病、中心性肥胖、高血压和糖尿病。及早发现这一病症对于及时采取干预措施和预防并发症的发生至关重要。
{"title":"Abdominal Obesity-Metabolic Syndrome 3 Misclassified as Type 1 Diabetes Mellitus.","authors":"Suhaib Radi, Lujain Bashamakh, Hayfa Mandourah, Sarah Alsharif","doi":"10.1210/jcemcr/luae120","DOIUrl":"10.1210/jcemcr/luae120","url":null,"abstract":"<p><p>Age is no longer the most important differentiating feature between type 1 and type 2 diabetes, as obesity and metabolic syndrome are on the rise in the pediatric population. Here we present a case of a 30-year-old male individual initially diagnosed with uncontrolled type 1 diabetes mellitus (T1DM) since the age of 15, and treatment with high insulin doses has been unsuccessful. He was later identified as having abdominal obesity-metabolic syndrome 3 (AOMS3) based on strong family history and the presence of insulin resistance features. AOMS3 is characterized by early-onset coronary artery disease, central obesity, hypertension, and diabetes. Early detection of this condition is crucial to implement timely interventions and preventing the onset of complications.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"2 8","pages":"luae120"},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JCEM case reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1